anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
BACKGROUND/AIM: Cancer-induced bone pain (CIBP) is one of the most common symptoms of bone metastasis of tumor cells. The hypothalamus may play a pivotal role in the regulation of CIBP. However, little is known about the exact mechanisms.
MATERIALS AND METHODS: First, we established a CIBP model to explore the relationship among hypothalamic ghrelin, NPY and CIBP. Then, we exogenously administered NPY and NPY receptor antagonists to investigate whether hypothalamic NPY exerted an antinociceptive effect through binding to NPY receptors. Finally, we exogenously administered ghrelin to investigate whether ghrelin alleviated CIBP by inducing the production of hypothalamic NPY through the AMPK-mTOR pathway. Body weight, food intake and behavioral indicators of CIBP were measured every 3 days. Hypothalamic ghrelin, NPY and the AMPK-mTOR pathway were also measured.
RESULTS: The expression of hypothalamic ghrelin and NPY was simultaneously decreased in cancer-bearing rats, which was accompanied by CIBP. Intracerebroventricular (i.c.v.) administration of NPY significantly alleviated CIBP in the short term. The antinociceptive effect of NPY was reversed with the i.c.v. administration of the Y1R and Y2R antagonists. The administration of ghrelin activated the AMPK-mTOR pathway and induced hypothalamic NPY production to alleviate CIBP. This effect of ghrelin on NPY and antinociception was reversed with the administration of a GHS-R1α antagonist.
CONCLUSION: Ghrelin could induce the production of hypothalamic NPY through the AMPK-mTOR pathway to alleviate CIBP, which can provide a novel therapeutic mechanism for CIBP.
The rTMS was administered once a day, implementing approximately 10-20 minutes of physical therapy, with stimulation parameters of 10 Hz frequency, 120% MT intensity, and 50 treatment sequences of 60 stimulations each, with 30-second intervals between the sequences, for a total of 3000 stimulations. For medication: If the depressive episode is only monophasic, give sertraline hydrochloride tablets 1-2 tablets/day for treatment； if the patient has bipolar disorder-depressive episode, give the emotion stabilizer lithium carbonate tablets 0.5-1.0 g/day (adjust the dose according to the blood concentration) for treatment.
The present invention provides peptides consisting of L- and/or D-amino acids and combinations thereof, which affect myeloid cells by action on the triggering receptors expressed on myeloid cells (TREMs), including TREM-I and TREM-2. More specifically, however, the peptides act on the TREM/DAP-12 signaling complex. The invention also provides lipid and sugar conjugated peptides comprising L- or D-amino acids. The invention still further provides a method of designing of the peptides and lipid- and/or sugar-conjugated peptides comprising L- or D- amino acids. The present invention further relates to the therapy of various myeloid cell- related disease states involving the use of these peptides and compounds. Specifically, the peptides and compounds are useful in the treatment and/or prevention of a disease or condition where myeloid cells are involved or recruited. The peptides of the present invention also are useful in the production of medical devices comprising peptide matrices (for example, medical implants and implantable devices). Compositions described in my invention can be used commercially as therapeutic agents to treat myeloid cell-related disorders. A non-exhaustive list of disorders in which myeloid cells are involved/recruited include: cancer, allergic diseases, inflammatory bowel disease, acute mesenteric ischemia, hemorrhagic shock, autoimmune diseases, including but not limited to, rheumatoid arthritis and other rheumatic diseases, sepsis and other inflammatory or other condition involving myeloid cell activation.
This group will receive nebulized ropivacaine 0.5% based on ideal body weight at a dose of 0.5 mg/kg with a maximum total dose of 30 mg. This will be administered once at the onset of pneuomoperitoneum during appendectomy.
General Study Design: The proposed study is a double-blind, randomized control trial of permethrin-treated lesus to prevent P. falciparum malaria in children 6-24 months of age conducted at two sites in rural western Uganda. Participating mother-infant pairs will receive a new bed net and two permethrin-treated or untreated lesus at enrollment. The total sample size will be 400 mother-infant pairs with 200 pairs in each group. The investigators will follow participants longitudinally for six months. Participants will be instructed and incentivized to present to one of the two study clinics when a fever develops, where they will be evaluated, tested, and treated, if positive, for malaria. Participants will also attend scheduled clinic visits every two weeks for routine surveillance of adverse effects and to test for asymptomatic infection. Re-treatment and sham re-treatment of lesus will occur each month.

Outcome Measures: The primary outcome measure is the incidence rate ratio of clinical (i.e., symptomatic) P. falciparum malaria in infants and children 6 - 24 months of age. Differences in malaria infection between treatment groups will be estimated with the incidence rate ratio, defined as the ratio of the number of clinical malaria episodes per 100 person-weeks at risk in the intervention group relative to the control group. This measure was chosen as it represents the most patient-centered measure of malaria burden, reflecting not only the potential negative health consequences, but also opportunity costs associated with care seeking and treatment.
The invention relates to a food therapy preparation for preventing and treating constipation based on the theories of preventive treatment of disease and medicine food homology, which is characterized by comprising the effective ingredients of the following raw materials in weight ratio: 6-8 semen cannabis, 6-8 bunge cherry seeds, 4-6 cape jasmine fruit, 6-8 cassia seeds and 4-6 radish seeds. The prescription of the food therapy preparation is based on the theory of preventive treatment of disease, and the food therapy preparation is prepared from a sufficient amount of effective ingredients. Although the food therapy preparation is not a medicine, the actions of the medicine can be exerted. The food therapy preparation not only can greatly limit the occurrence and the development of the constipation, but also can save a great amount of medical resources and investments for China simultaneously. People can conveniently and correctly select the food therapy preparation in a pertinence way according to early symptoms per se to prevent the possible occurrence of the constipation, and thus, the purposes of disease prevention and body building are achieved. The food therapy preparation can be directly taken according to a certain amount, and can also be eaten together with foods and drinks as an additive of the foods and the drinks.
The present invention relates to the promotion of tissue turnover by the administration of one or more wound healing modulators. The wound healing modulator may be selected from appropriate wound healing agents and binding partners, and particularly agents that enhance wound healing. The agent may comprise advanced glycosylation endproducts (AGEs), compositions and complexes containing advanced glycosylation endproducts, derivatives thereof, and mixtures thereof. The AGEs constituting agents may particularly comprise the reaction product of a sugar selected from the group consisting of glucose, glucose-6-phosphate, fructose and ribose; and a protein selected from the group consisting of collagen, albumin, ribonuclease, avidin, and mixtures thereof. Diagnostic and therapeutic utilities are proposed, the latter including the treatment of wound healing dysfunction, the promotion of transplant tissue acceptance and the promotion of hair growth. Pharmaceutical compositions and prosthetic materials are likewise contemplated and set forth.
Participants will not receive TENS intervention during the first 4 weeks of the trial but will complete all testing procedures as the other two arms. This group will receive active TENS during the last 4 weeks of the study.
Liver failure secondary to metabolic dysfunction-associated steatotic liver disease (MASLD) has become the most common cause for liver transplantation in many parts of the world. Moreover, the prevalence of MASLD not only increases the demand for liver transplantation, but also limits the supply of suitable donor organs because steatosis predisposes grafts to ischemia-reperfusion injury (IRI). There are currently no pharmacological interventions to limit hepatic IRI because the mechanisms by which steatosis leads to increased injury are unclear. To identify potential novel mediators of IRI, we used liquid chromatography and mass spectrometry to assess temporal changes in the hepatic lipidome in steatotic and non-steatotic livers after warm IRI in mice. Our untargeted analyses revealed distinct differences between the steatotic and non-steatotic response to IRI and highlighted dynamic changes in lipid composition with marked changes in glycerophospholipids. These findings enhance our knowledge of the lipidomic changes that occur following IRI and provide a foundation for future mechanistic studies. A better understanding of the mechanisms underlying such changes will lead to novel therapeutic strategies to combat IRI.
PURPOSE: An ovotransferrin hydrolysate and a composition containing the same for anticancer are provided to remove peroxyl radical and to inhibit leukocyte DNA damage. CONSTITUTION: A method for preparing an ovotransferrin hyrolysate comprises: a step of mixing egg white ovotransferrin with enzyme in a weight ratio of 25:1 and adjusting by pH 2.5-7.0; a step of reaction of the mixture at 45 Deg. C. for 3 hours and heating at 100 Deg. C. for 10 minutes; and a step of centrifuging the mixture at 3,000 rpm for 20 minutes and freeze-drying the supernatant. The enzyme is pepsin, protamax, alcalase, trypsin, neutrase, flavorzyme, collupulin, protex, A-chymotrypsin, promod, or collupulin. An anticancer composition contains the ovotransferrin hydrolysate as an active ingredient.
There are limited data on overdose with ZIAC. However, several cases of overdose with bisoprolol fumarate have been reported (maximum: 2000 mg). Bradycardia and/or hypotension were noted. Sympathomimetic agents were given in some cases, and all patients recovered.

The most frequently observed signs expected with overdosage of a beta-blocker are bradycardia and hypotension. Lethargy is also common, and with severe overdoses, delirium, coma, convulsions, and respiratory arrest have been reported to occur. Congestive heart failure, bronchospasm, and hypoglycemia may occur, particularly in patients with underlying conditions. With thiazide diuretics, acute intoxication is rare. The most prominent feature of overdose is acute loss of fluid and electrolytes. Signs and symptoms include cardiovascular (tachycardia, hypotension, shock), neuromuscular (weakness, confusion, dizziness, cramps of the calf muscles, paresthesia, fatigue, impairment of consciousness), gastrointestinal (nausea, vomiting, thirst), renal (polyuria, oliguria, or anuria [due to hemoconcentration]), and laboratory findings (hypokalemia, hyponatremia, hypochloremia, alkalosis, increased BUN [especially in patients with renal insufficiency]).

If overdosage of ZIAC (bisoprolol fumarate and hydrochlorothiazide) is suspected, therapy with ZIAC should be discontinued and the patient observed closely. Treatment is symptomatic and supportive; there is no specific antidote. Limited data suggest bisoprolol fumarate is not dialyzable; similarly, there is no indication that hydrochlorothiazide is dialyzable. Suggested general measures include induction of emesis and/or gastric lavage, administration of activated charcoal, respiratory support, correction of fluid and electrolyte imbalance, and treatment of convulsions. Based on the expected pharmacologic actions and recommendations for other beta-blockers and hydrochlorothiazide, the following measures should be considered when clinically warranted:
NEW MATERIAL:The compound of formula (the 105-Cys is bonded with the 121- Cys through disulfide bond) called as gamma-hANP, and its salt. USE:Hypotensor and diuretic. PREPARATION:The human arterium is extracted, homogenized in the presence of 1N nitric acid, and extracted with cold acetone. The extract is centrifuged, and acetone is removed from its supernatant liquid by vacuum distillation to obtain extract liquid. The liquid is added with water, subjected to the reverse- phase column chromatography, eluted, and freeze-dried to obtain a solid product. The solid is dissolved in 1N acetic acid, and filtered by gel-filtration to obtain a fraction active to relax the chick ileum specimen. The fraction is subjected to liquid chromatography, and eluted by linear gradient method using a mixture of water, acetone and 10% trifluoroacetic acid. The peak fraction is subjected again to chromatography, and principal peak is collected to obtain pure gamma-hANP.
Subjects will receive placebo, orally, BID on Days 1 to 10. Subjects will receive each dose after either fed or fasted conditions. Part B will be initiated based on the review of all safety, tolerability and PK data from Part A.
FIELD: medicine. SUBSTANCE: method involves concentration of birch soap by vacuum-evaporation up to the content 30-38% and addition of high-dispersed silica with developed surface 280-350 m 2 /g at concentration 100 mas. p. of concentrate per 0.2-5 mas. p. of silica following by stirring for 17-24 h, filtration and drying. Preparation obtained shows ability to decrease sugar level after alloxan administration. EFFECT: improved method of active agent preparing.
PURPOSE: To obtain a ski preparation for external use formulated with saponin(s) extracted from specific plant (s), excellent in skin beautifying effect, and good in both usability and safety. CONSTITUTION: This skin preparation for external use contains, as active ingredient, 0.001-20wt.% of at least one kind of saponin or its salt extracted from Pulsatilla cernua Spreng., Cyclamen europaeum, Primula officinalli, Achyranthes fauriei Lev. et Van., Fatsia japonica Decne. et Pianch, Caulophyllum robustum Maxim., Clematis chinensis Osbeek, and Anemarrhena asphodeloides Bunge. Besides, combination of the active ingredient with an ascorbic phosphoric ester and/or placenta extract potentiates the skin beautifying effect of this skin preparation, and prevents skin spots and freckle to cause the fine and dampish skin. This skin preparation can be made, by conventional means, into cosmetics and medicinal preparations of such formulations as milky lotion, lotion, cream, jelly, pack, powder, and ointment.
Glioblastoma multiforme (GBM) is an aggressive form of brain cancer. Biomarkers for GBM that provide prognostic and predictive information are useful because they provide the physician valuable information regarding treatment options for GBM. The present invention provides a method to quantify such biomarkers. Thus, the method relates to the quantification of GSK3β, S6, CREB, PTEN, AKT and mTOR biomarkers and the use of AQUA® analysis to estimate a patient's risk and benefit to treatment using an inhibitor of the AGC-family kinase. Unlike traditional IHC, the AQUA® system is objective and produces quantitative in situ protein expression data on a continuous scale. The present invention uses the AQUA system to provide a robust and standardized diagnostic assay that can be used in a clinical setting to provide prognostic and predictive information.
The invention relates to a medicine for treating leukopenia after chemoradiotherapy, which belongs to the medicine technical field, and concretely relates to the medicine for treating leukopenia after chemoradiotherapy. The medicine for treating leukopenia after chemoradiotherapy comprises the following integrates by weight: 20g of crude astragali radix, 20g of codonopsis pilosula, 20g of radix pseudostellariae, 40g of caulis Spatholobi, 20g of crude fleece-flower root, 10g of white paeony root, 10g of Chinese angelica, 10g of Morinda officinalis, 20g of large Rehmannia Glutinosa, 15g of pyrrosia lingua, 15g of large red jujube. A conventional method for the preparation of Chinese traditional medicine preparation is employed for preparing particles or oral liquids. The medicine provided by the invention can be taken three times a day (the administration amount for each time equals 50g of decoction of the integrates), and one course of treatment lasts for five days. The medicine of the invention is used for treating leukopenia after chemoradiotherapy, the side effect is little, and feeling of body ache is not generated. In clinic treatment, 68 cases are recorded, wherein 64 cases are recovered, in 6 unsatisfactory cases, 4 cases have increased leukocyte without standard achievement, and 2 cases are invalid, and the recovery rate is 94%.
Surgery on the thoracic aorta often requires a brief period of deep hypothermic circulatory arrest (DHCA). The most feared complication of aortic surgery is neurological injury, which can range from mild cognitive impairment to more severe injuries such as stroke. Due to the significant morbidity and mortality associated with post-operative stroke and neurological dysfunction, cerebral protection techniques have evolved extensively. A recommended approach to cerebral protection during DHCA is to deliver blood to the brain in an antegrade fashion via the arterial system, so called antegrade cerebral perfusion (ACP). Axillary artery cannulation, a form of ACP, has become the preferred method of neuroprotection for aortic operations requiring DHCA. However, axillary artery cannulation requires more surgical time and presents potential complications such as brachial plexus injury, seromas, and limb ischemia. The present study aims to determine whether a less common alternative strategy, innominate artery cannulation, offers similar neuroprotection compared to axillary artery cannulation and reduces operative times. A total of 110 patients undergoing elective aortic surgery will be randomly assigned to one of the two strategies. The primary outcome will be the number of patients with new ischemic lesions found on post-operative diffusion weighted MRI (DW-MRI) and total operative time.
The invention discloses a Uyghur herbal medicine for treating diabetes mellitus. The medicine is prepared from fructus mume, radix ginseng rubra, bitter melon seeds, walnut kernels, bottle gourd seeds, pomegranate blossom, cinnamon seeds, purslane seeds, polygonatum kingianum, asparagus lettuce seeds, safflower carthamus, hemerocallis fulva, lotus, opium seeds, cichory seeds and the like. According to differences between hot and cold constitutions of patient bodies, diabetes mellitus is divided into hot diabetes mellitus and cold diabetes mellitus. The Uyghur herbal medicine is specifically used for treating hot diabetes mellitus. Four medicinal materials are scientifically matched and reasonably combined, and effective ingredients of the medicinal materials are directly against the root cause of diabetes mellitus. The medicine is a blood sugar inhibitor and an insulin sensitizer, can be used for reinforcing the function of an insulin receptor, effectively inhibiting generation of blood sugar toxin, repairing B cells secreted in injured insulin, promoting islet cells to normally release insulin and quickly reducing blood sugar. According to the Uyghur herbal medicine, the effective rate is 98 percent, and the cure rate is 92 percent; 15 days are taken as a course of treatment, and diabetes mellitus can be cured after three courses of treatment.
PURPOSE: To obtain a cosmetic free from color fading and color unevenness, excellent in color tone and stability over time, by blending a multiple oxide of Ti, Ni and Sb in a cosmetic containing or filled with an organic solvent. CONSTITUTION: This cosmetic is obtained by blending 0.001-5wt.%, based on the whole cosmetic, of a multiple oxide of Ti, Ni and Sb in a cosmetic containing or filled with an organic solvent in its formulation. The multiple oxide is a yellow color-based pigment, and is prepared by incorporating titanium dioxide as the chief component with nickel oxide and antimony oxide as color developers. The composition of the multiple oxide is e.g. such that the weight ratio titanium dioxide/antimony oxide/nickel oxide stands at (16:3:1). This cosmetic is specifically, for example, in the form of manicure, slurry-molded eyecolor, rouge, etc.
Pain caused by osteoarthritis is a matter of huge impact, in terms of quality of life, social and economic burden. Global aging of the population is going to worsen the problem. The hand is the most affected site in the upper limb, and involvement of the trapeziometacarpal joint is highly prevalent, with significant limitation of functionality when it happens. In the lower limb, the hip and the knee share the leading position in the clinical scenario, with the former being historically the most frequently submitted to joint replacement.

At any site, the vast majority of joint replacement surgery procedures are performed because of pain. MRgFUS has recently demonstrated a great potential in treating pain caused by different medical conditions, including osteoarthritis. The aim of the work is to study the feasibility, the safety and the potential efficacy of MRgFUS in treating pain from osteoarthritis in two "hot" spots: the hip and the trapeziometacarpal/scaphotrapezial joint.
Many techniques for one lung ventilation exist including the use of double-lumen tubes, endotracheal tubes and bronchial blockers. The choice of lung isolation technique depends on the age, the size of the patient, experience of the anaesthetist and type of the surgery. The use of double lumen tube for one lung ventilation is very common. However, it may be challenging and hazardous in some cases such as pediatric patients, patients with tracheostomy, difficult airway scenarios. Endobronchial blockers can be used for these cases. Bronchial blockers have high-volume,low-pressure balloons so they are less likely to cause damage to the airway mucosa while achieving a successful lung isolation. Arndt blocker has a low-pressure, high-volume balloon, a multiport airway adapter and a guide loop. On the other hand, Tappa bronchial blocker has an auto inflation balloon, and a high volume low pressure cuff. It also has 'Tappa angle' which is designed as per human anatomy which makes it easier to insert.

In our study, we aim to compare the efficacy and ease of placement of Arndt and Tappa blocker for pediatric one lung ventilation. Our primary outcome is the time from laryngoscopy to successful insertion of the bronchial blocker by an experienced anaesthetist. Secondary outcomes are effects of two different bronchial blockers on lung isolation score, ease of placement of the bronchial blocker, mechanical ventilation parameters (tidal volume, respiratory rate, peak airway pressure, plateau pressure, compliance), intraoperative blood gas analysis (paO2, pCO2, saO2, lac), frequency of malposition after successful blocker placement, surgical exposure and complications. The difficulty of placement of the blocker will be assesed by a 5-point scale (1:very easy, 5:impossible) and the lung collapse will be evaluated by using a 10-point scale (10: complete collapse).